RxDoctor Payments Data

Ajay Reddy, MD

Cardiovascular Disease · Elkhorn, WINPI 1366654865

Payments from drug & device makers

$1,834in general payments, 2019–2025

Across 72 payments — averaging $25.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$562
  • Exelixis Inc.$175
  • Merck$170
  • AstraZeneca$162
  • Novartis$113
  • Otsuka America Pharmaceutical, Inc.$109
  • plus $543 from 10 others

What the payments were for

  • Food & beverage$1,834100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,834 in reported general payments places this provider in the 55th percentile of 322 cardiovascular disease providers in Wisconsin.

See all cardiovascular disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$87,483
Medicare patients
668
Services billed
1,335

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban174$184,426
OzempicSemaglutide155$160,918
EntrestoSacubitril/Valsartan82$77,305
JardianceEmpagliflozin70$64,938
WegovySemaglutide39$52,030
MounjaroTirzepatide36$41,332
XareltoRivaroxaban27$33,185
Varenicline Tartrate74$14,670
Repatha SureclickEvolocumab20$12,707
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$10,544
Repatha SyringeEvolocumab18$9,645
Metoprolol Succinate472$5,119
VascepaIcosapent Ethyl14$4,847
Hydrochlorothiazide546$2,299
Clonidine11$1,984

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$73$212,947194 claims
NovartisEntresto$113$77,30582 claims
Boehringer IngelheimJardiance$80$64,93870 claims
Lilly USA, LLCMounjaro$66$41,33236 claims
GSKTrelegy Ellipta$68$10,54414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 322 cardiovascular disease providers in Wisconsin.

Other cardiovascular disease in Elkhorn

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →